Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2026)
Vivos Therapeutics (VVOS) reported Retained Earnings of -$133.0 million for Q1 2026, down 23.03% year-over-year from -$172.8 million in Q1 2025, and down 6.1% quarter-over-quarter from -$125.4 million in Q4 2025.
Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 8 years of Retained Earnings data on file, last reported at -$133.0 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$133.0 million, down 23.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$133.0 million (down 23.03% YoY), and the FY2025 annual result was -$125.4 million, down 20.32% from the prior year.
- Retained Earnings fell to -$133.0 million in Q1 2026 per VVOS's latest filing, from -$125.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$61.0 million in Q1 2022 and troughed at -$133.0 million in Q1 2026.
- A 5-year average of -$95.9 million and a median of -$96.8 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings tumbled 58.84% in 2022, then slipped 11.67% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$79.5 million in 2022, then slipped by 17.09% to -$93.1 million in 2023, then declined by 11.97% to -$104.2 million in 2024, then declined by 20.32% to -$125.4 million in 2025, then fell by 6.1% to -$133.0 million in 2026.
- Business Quant data shows VVOS's Retained Earnings at -$133.0 million in Q1 2026, -$125.4 million in Q4 2025, and -$118.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 49.96 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -583.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 32.30 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -398.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -221.30 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 106.20 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 5.65 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -113.10 Mn |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -133.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -133.00 Mn |
| Dec 31, 2025 | -125.36 Mn |
| Sep 30, 2025 | -118.50 Mn |
| Jun 30, 2025 | -113.06 Mn |
| Mar 31, 2025 | -108.10 Mn |
| Dec 31, 2024 | -104.19 Mn |
| Sep 30, 2024 | -101.40 Mn |
| Jun 30, 2024 | -98.70 Mn |
| Mar 31, 2024 | -96.80 Mn |
| Dec 31, 2023 | -93.05 Mn |
| Sep 30, 2023 | -88.80 Mn |
| Jun 30, 2023 | -86.70 Mn |
| Mar 31, 2023 | -81.17 Mn |
| Dec 31, 2022 | -79.47 Mn |
| Sep 30, 2022 | -73.40 Mn |
| Jun 30, 2022 | -67.95 Mn |
| Mar 31, 2022 | -60.95 Mn |
| Dec 31, 2021 | -55.62 Mn |
| Sep 30, 2021 | -48.23 Mn |
| Jun 30, 2021 | -42.78 Mn |